Angiotensin II receptor antagonists

Détails

ID Serval
serval:BIB_50C4A9A0887B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Angiotensin II receptor antagonists
Périodique
Lancet
Auteur(s)
Burnier  M., Brunner  H. R.
ISSN
0140-6736 (Print)
Statut éditorial
Publié
Date de publication
02/2000
Volume
355
Numéro
9204
Pages
637-45
Notes
Journal Article
Review --- Old month value: Feb 19
Résumé
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors. However, ACE is a non-specific target for blocking the renin-angiotensin enzymatic cascade. The availability of orally active drugs turned ACE inhibition into a therapeutic breakthrough but more specific blockade always seemed desirable. This goal has now been achieved with the orally active angiotensin II receptor antagonists; six are on the market and more are under development. This new class of drugs is equal in efficacy to ACE inhibitors, at least in hypertensive patients. Trials now underway will demonstrate whether angiotensin II receptor antagonists can prevent target-organ damage and reduce cardiovascular morbidity and mortality. If they do, these compounds might one day replace ACE inhibitors.
Mots-clé
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use Animals Antihypertensive Agents/*therapeutic use Clinical Trials Dogs Humans Hypertension/*drug therapy Receptors, Angiotensin/*antagonists & inhibitors Renin-Angiotensin System/drug effects Safety
Pubmed
Web of science
Création de la notice
25/01/2008 13:56
Dernière modification de la notice
03/03/2018 17:09
Données d'usage